VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
3 hedge funds and large institutions have $1.46M invested in VALEANT PHARMACEUTICALS INTL in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
38% more capital invested
Capital invested by funds: $1.05M → $1.46M (+$404K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cullinan Associates
Louisville,
Kentucky
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
-$93.1K |
VRX Hedge Fund Activity: Q2 2018 in Review
3 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q2 2018, worth a combined $1.46M — up 38% from $1.05M a quarter earlier.
Fund positioning in VRX was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Cullinan Associates, adding an estimated $11.6K. The largest seller was Baxter Bros Inc, cutting an estimated $93.1K.
- 3 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.46M of VALEANT PHARMACEUTICALS INTL stock for Q2 2018, up 38% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q2 2018 and 0 closed out.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q2 2018 was Cullinan Associates, an estimated $11.6K added.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q2 2018 was Baxter Bros Inc, an estimated $93.1K sold.
Based on aggregated 13F filings for Q2 2018.